FDA approves ML6710i photodynamic laser for use with Visudyne
Click Here to Manage Email Alerts
The FDA has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s Visudyne photodynamic therapy for the treatment of classic subfoveal choroidal neovascularization due to age-related macular degeneration.
According to a press release from Bausch + Lomb and Modulight, the ML6710i is a transportable ophthalmic laser that is controlled using an iPad mobile application. The laser’s beam shaping unit can be fit into common slit lamps and formed into a circular, uniform spot for Visudyne (verteporfin for injection) delivery.
Source: Adobe Stock.
“PDT continues to be an important treatment option for eye care professionals who are looking to treat patients with predominantly classic subfoveal choroidal neovascularization,” Christina Ackermann, president of ophthalmic pharmaceuticals at Bausch + Lomb, said in the release. “With the approval of ML6710i, eye care professionals now have a new state-of-the-art photodynamic laser that addresses a significant unmet need in PDT and is specifically designed to deliver Visudyne to patients who suffer from wet AMD with persistent fluid.”
ML6710i is expected to be available in the first half of the year.
Read more about
Click Here to Manage Email Alerts